On May 30, 2025, Sonnet BioTherapeutics received a notice from Nasdaq stating that it does not meet the minimum stockholders’ equity requirement of $2.5 million, reporting only $662,262. The company has 45 days to submit a plan to regain compliance, or it risks delisting from Nasdaq.